用 inclisiran 治疗高胆固醇血症。

Q4 Medicine

Ugeskrift for laeger Pub Date : 2024-06-10 DOI:10.61409/V12230767

Nerma Todorovac, Michael Skov Hansen, Frank Peter Elpert

{"title":"用 inclisiran 治疗高胆固醇血症。","authors":"Nerma Todorovac, Michael Skov Hansen, Frank Peter Elpert","doi":"10.61409/V12230767","DOIUrl":null,"url":null,"abstract":"In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.","PeriodicalId":23428,"journal":{"name":"Ugeskrift for laeger","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hypercholesterolaemia treated with inclisiran.\",\"authors\":\"Nerma Todorovac, Michael Skov Hansen, Frank Peter Elpert\",\"doi\":\"10.61409/V12230767\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.\",\"PeriodicalId\":23428,\"journal\":{\"name\":\"Ugeskrift for laeger\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ugeskrift for laeger\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.61409/V12230767\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ugeskrift for laeger","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.61409/V12230767","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

在这份病例报告中，一名 31 岁的杂合子家族性高胆固醇血症（FH）女性患者接受了他汀类药物和 PCSK9 抑制剂治疗，但由于肌酸激酶水平升高以及神经和肌肉副作用而不得不停止治疗。2021 年，该患者接受了 inclisiran 治疗，这是丹麦首次应用该疗法。治疗过程中未出现任何副作用，低密度脂蛋白胆固醇水平显著降低。本病例报告强调了 inclisiran 作为一种有效且耐受性良好的治疗方法对杂合性 FH 患者的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Hypercholesterolaemia treated with inclisiran.

In this case report, a 31-year-old woman with heterozygous familial hypercholesterolaemia (FH) underwent treatment with statins and PCSK9 inhibitor but had to discontinue due to elevated creatine kinase levels and neurological and muscular side effects. In 2021, the patient received inclisiran therapy, the first known instance of its application in Denmark. No side effects were reported, and LDL cholesterol levels were significantly reduced. This case report highlights the potential of inclisiran as an effective and well-tolerated treatment for individuals with heterozygous FH.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ugeskrift for laeger Medicine-Medicine (all)

CiteScore

0.20

自引率

0.00%

发文量

345

期刊介绍： The Ulster Medical Journal is an international general medical journal with contributions on all areas of medical and surgical specialties relevant to a general medical readership. It retains a focus on material relevant to the health of the Northern Ireland population. The Honorary Editor would welcome offers of papers for publication. Prospective authors are invited to read the notice to contributors.